How should a 35-year-old female with a one-year history of treatment‑refractory melanoma be managed?

Management of Treatment-Resistant Melanoma in a 35-Year-Old Female

For a 35-year-old female with one-year treatment-refractory melanoma, immediately confirm BRAF mutation status and initiate combination immunotherapy with nivolumab plus ipilimumab as first-line systemic therapy if not already tried, or consider neoadjuvant immunotherapy if disease is resectable stage III/IV. 1, 2

Initial Assessment and Molecular Testing

Before proceeding with treatment decisions, you must:

• Confirm BRAF mutation status - this is critical as it fundamentally changes your treatment approach 2
• Restage the disease completely to determine if this is resectable stage III, resectable stage IV, or unresectable metastatic disease
• If BRAF testing was done previously and showed wild-type, consider retesting upon progression (though rarely changes management) 2
• Assess performance status - note that poor performance from tumor burden may actually improve with systemic therapy initiation 2

Treatment Algorithm Based on Disease Stage

For Resectable Stage III or Resectable Stage IV Disease:

Neoadjuvant immunotherapy is now the preferred approach based on the groundbreaking S1801 trial data. The rationale: administering anti-PD-1 therapy before surgery activates a larger population of tumor-infiltrating T cells, inducing systemic immune responses at both local and distant sites 1. This approach preserves more antitumor T cells compared to adjuvant therapy where surgical resection removes many of these cells with the tumor specimen.

• Administer PD-1 blockade before surgical resection
• Follow with wide excision (margins based on Breslow thickness)
• Consider sentinel lymph node biopsy for pathologic staging
• Radiation therapy may be added to nodal basin in high-risk cases (large nodes, multiple involved nodes, extracapsular extension), though weigh lymphedema risk 1

For Unresectable Metastatic Disease:

If BRAF-Mutated:

You have two equally valid first-line options:

• Combination immunotherapy: Nivolumab plus ipilimumab followed by nivolumab maintenance
• Targeted therapy: BRAF/MEK inhibitors

The choice depends on toxicity tolerance and urgency of response. Targeted therapy provides faster responses but immunotherapy may offer more durable benefit 1, 2.

If BRAF Wild-Type:

Combination immunotherapy is preferred: Nivolumab plus ipilimumab followed by nivolumab maintenance 2

Alternative if combination contraindicated or refused:

• Single-agent PD-1 inhibitor (nivolumab or pembrolizumab)
• T-VEC for injectable lesions (though inferior to immunotherapy) 2

Critical Management Considerations

Toxicity monitoring is paramount - maintain high suspicion for immune-related adverse events. Combination ipilimumab/nivolumab has significantly higher toxicity than monotherapy, but current efficacy measures may underestimate the true benefit difference 2. Ensure treatment occurs where immune-related toxicity can be properly managed.

If disease progresses on first-line immunotherapy, options include:

• Cytotoxic chemotherapy (cisplatin/dacarbazine) - despite traditional teaching, some refractory patients achieve meaningful responses 3
• High-dose radiation combined with continued immunotherapy for oligometastatic disease 4
• Clinical trial enrollment should be strongly considered before resorting to older therapies like IL-2 2

Special Situations

Brain metastases: If asymptomatic brain metastases develop, nivolumab plus ipilimumab shows 46-57% intracranial response rates versus 20% for nivolumab alone (though formal ASCO brain metastases guidelines are forthcoming) 2.

Autoimmune disease: Immunotherapy may be given with caution, though toxicity risk is higher 2.

Common Pitfalls to Avoid

• Don't assume poor performance status precludes systemic therapy - if tumor-related, it may improve with treatment
• Don't rely solely on RECIST criteria to judge immunotherapy efficacy - these measures don't fully capture true benefit 2
• Don't overlook the potential for conventional chemotherapy in truly refractory cases - paradigm shifts don't eliminate all older options 3
• Don't forget that "treatment-resistant" requires confirmation of adequate prior therapy - ensure previous treatments were appropriate and adequately dosed

Clinical trial enrollment remains the gold standard for any melanoma patient and should be actively pursued 1.